Elinor Shin is passionate about improving women’s healthcare and advancing scientific innovation and knowledge to understand and treat diseases. She has over 25 years in the healthcare industry. She is currently Senior Vice President of Legal and Intellectual Property at Ensoma, Inc, a company dedicated to developing therapies for treating complex diseases using in vivo genome editing. Prior to joining Ensoma, Elinor served as Senior Vice President of Legal and corporate secretary for Chroma Medicine, Inc., a company focused on therapies that utilize epigenetic editing. As Vice President of Intellectual Property at MyoKardia, Inc., Elinor was responsible for building its’ Intellectual Property department and was fortunate witness the outstanding Phase III results of its groundbreaking new drug for hypertrophic cardiomyopathy, Camzyos. Prior to MyoKardia, Elinor spent several years at Genentech, Inc., in roles of increasing responsibility, eventually a team of legal professionals handling the intellectual property of Roche’s US non-oncology medicines and Genentech’s non-oncology pipeline worldwide.
Previous to Genentech, Elinor was an attorney and patent agent in the law office of Fish & Neave. Elinor holds a PhD in Biochemistry from Tufts University and a JD from Fordham University.
Lyn Behnke, MSN, DNP
Dr. Lyn Behnke, a WomenHeart Champion, has a long and varied career as a primary care provider, a critical care nurse,...
